New Results from ENVISION Phase 3 Study of GIVLAARI® (givosiran) Presented at EASL Congress 2024

New Results from ENVISION Phase 3 Study of GIVLAARI® (givosiran) Presented at EASL Congress 2024

New results from a post hoc subgroup analysis of the ENVISION Phase 3 study evaluating long-term outcomes in patients with acute hepatic porphyria who were not attack-free after the first six months of GIVLAARI® (givosiran) treatment were presented at the European Association for the Study of the Liver (EASL) Congress 2024.

Ventura, et al. “Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6 months of givosiran treatment in a subgroup analysis of the phase 3 ENVISION study”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.